Straits Times Index
3,342.54 +5.95 (+0.18%) Nikkei
38,929.43 +441.53 (+1.15%) Hang Seng
18,297.82 +218.21 (+1.21%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
68,168.52 +408.91 (+0.60%) CMC Crypto 200
1,474.14 +45.57 (+3.19%)
LLY Mar 2025 800.000 put
- PR Newswire
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
- Zacks
Top Research Reports for Eli Lilly, T-Mobile & BHP
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
- Insider Monkey
Is Eli Lilly And Co (NYSE:LLY) the Best Weight Loss Stock to Buy in 2024?
We recently published a list of Jim Cramer’s Top 10 Stock Picks for June. Since Eli Lilly And Co (NYSE:LLY) ranks higher in the list, the stock deserves a deeper look. But first, let’s see what Cramer was talking about during his programs earlier this week. Jim Cramer in a latest program lamented over Salesforce’s […]
